P2Y12 Inhibitors

Platelet Inhibition With the P2Y12 Inhibitor Cangrelor

10/06/2019

Cath Lab Digest talks with Tom A. Lassar, MD, Sarver Heart Center,
University of Arizona College of Medicine, Tucson, Arizona.

Cath Lab Digest talks with Tom A. Las...

Think of the P2Y12 receptor as being shaped like a crown. If you drop a ball into the central part of the crown, that is the ADP site of the receptor. Clopidogrel, prasugrel, and cangrelor occupy that central site. Ticagrelor, however, is a...

Think of the P2Y12 receptor as...

10/06/2019

Cath Lab Digest

The Short-Term Aggrastat Infusion Registry (STAIR): Evaluating the Safety and Efficacy of Heparin + Short-Term Tirofiban vs Bivalirudin in PCI

09/05/2019

Cath Lab Digest talks with J. Brent Muhlestein, MD, FAHA, FACC,
Co-Director of Cardiology Research, Intermountain Health Care and
Intermountain Medical Center, Salt Lake City, Utah; Professor of Medicine, University of Utah, Salt Lake City, Utah.

Cath Lab Digest talks with J. Brent M...

We compared patients with coronary artery disease who underwent PCI having received either scheduled, planned tirofiban with short-term infusion or planned bivalirudin, which most of the time was without any use of a GP IIb/IIIa receptor...

We compared patients with...

09/05/2019

Cath Lab Digest

Strategies to Circumvent the Delayed Mechanism of Action of Oral Antiplatelets in the Cardiac Catheterization Lab

02/03/2019

Cath Lab Digest talks with Mahir Elder, MD, Clinical Professor at Wayne State University School of Medicine, Detroit, Michigan; Clinical Professor at Michigan State University College of Osteopathic Medicine, East Lansing, Michigan.

Cath Lab Digest talks with Mahir Elde...

The ongoing opioid crisis in this country, along with the judicial use of morphine in patients with acute coronary syndrome, have created an environment where it is important to bring awareness to physicians and medical staff about morphine,...

The ongoing opioid crisis in...

02/03/2019

Cath Lab Digest

Original Contribution

Prehospital Prasugrel Versus Ticagrelor in Real-World Patients With ST-Elevation Myocardial Infarction Referred for Primary PCI: Procedural and 30-Day Outcomes

10/15/2018

Nicola S. Vos, MD¹; Giovanni Amoroso, MD, PhD¹; Maarten A. Vink, MD, PhD¹; Moniek Maarse, MD²; Rob Adams, MSc³; Jean-Paul R. Herrman, MD, PhD¹; Mark S. Patterson, MD, PhD¹; Ren√® J. van der Schaaf, MD, PhD¹; Ton Slagboom, MD¹; Robbert J. de Winter, MD, PhD³

Nicola S. Vos, MD1; Giovanni Amoroso...

Pretreatment with P2Y12 inhibitors before primary percutaneous coronary intervention can reduce the incidence of major adverse cardiovascular event rate in ST-segment elevation myocardial infarction patients. We investigated differences in...

Pretreatment with P2Y12...

10/15/2018

Journal of Invasive Cardiology